Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 3, 2007, Pages 602-609

  González Rioja, Roberto ^a   Ibarrola, Ignacio ^a   Arilla, M Carmen ^a   Ferrer, Angel ^b   Mir, Amparo ^c   Andreu, Carmen ^b   Martínez, Alberto ^a   Asturias, Juan A ^a  

^a Research and Development Department   (Spain)

^b HOSPITAL VEGA BAJA   (Spain)

^c HOSPITAL FRANCESC DE BORJA   (Spain)

Author keywords

Hybrid proteins; IgE epitope; Parietaria pollen allergy; recombinant hypoallergens; T cell epitope

Indexed keywords

EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN E; PARIETARIA JUDAICA EXTRACT; PLANT EXTRACT; POLLEN ANTIGEN; RECOMBINANT HYBRID PROTEIN Q1; RECOMBINANT HYBRID PROTEIN Q2; RECOMBINANT HYBRID PROTEIN Q3; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HUMAN; IMMUNOREACTIVITY; NUCLEOTIDE SEQUENCE; PARIETARIA; PARIETARIA JUDAICA; POLLEN ALLERGY; POLYMERASE CHAIN REACTION; PRICK TEST; PRIORITY JOURNAL; PROTEIN BINDING; SKIN TEST; T LYMPHOCYTE; WESTERN BLOTTING;

ADOLESCENT; ADULT; ALLERGENS; BASE SEQUENCE; BLOTTING, WESTERN; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PARIETARIA; PLANT PROTEINS; POLLEN; POLYMERASE CHAIN REACTION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; SKIN TESTS;

EID: 34548267677     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.04.039     Document Type: Article

References (43)

1. Akdis C.A., and Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 121 (2000) 261-269
2. Akdis C.A., and Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 55 (2000) 518-524
3. Westritschnig K., and Valenta R. Can we genetically engineer safer and more effective immunotherapy reagents?. Curr Opin Allergy Clin Immunol 3 (2003) 495-500
4. Valenta R., and Linhart B. Molecular design of allergy vaccines. Curr Opin Immunol 17 (2005) 1-10
5. Ferreira F., Briza P., Inführ D., Schmidt G., Wallner M., Wopfner N., et al. Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5 (2006) 5-14
6. Akdis C.A., and Blasé K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Immunol 121 (2000) 261-269
7. Colombo P., Duro G., Costa M.A., Izzo V., Mirisola M., Locorotondo G., et al. An update on allergens. Parietaria pollen allergens. Allergy 53 (1998) 917-921
8. Colombo P., Bonura A., Costa M., Izzo V., Passantino R., Licorotondo G., et al. The allergens of Parietaria. Int Arch Allergy Immunol 130 (2003) 173-179
9. Costa M.A., Colombo P., Izzo V., Kennedy H., Venturella S., Cocchiara R., et al. cDNA cloning expression and primary structure of Par j I, a major allergen of Parietaria judaica pollen. FEBS Lett 341 (1994) 182-186
10. Duro G., Colombo P., Costa M.A., Izzo V., Porcasi R., DiFiore R., et al. cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollen. FEBS Lett 399 (1996) 295-298
11. Asturias J.A., Ibarrola I., Eseverri J.L., Arilla M.C., Gónzalez-Rioja R., and Martínez A. PCR-based cloning and immunological characterization of Parietaria judaica pollen profilin. J Invest Allergol Clin Immunol 14 (2004) 43-48
12. Trapani A, Gulino L, Bonura A, Artale A, Geraci D, Di Felice G, et al. Cross-reactive allergens of the Parietaria judaica pollen. In: Abstract Book for the XXV EAACI Congress; Vienna, Austria; June 10-14, 2006. p. 15.
13. Colombo P., Kennedy D., Ramsdale T., Costa M.A., Duro G., Izzo V., et al. Identification of an immunodominant IgE epitope of the Parietaria judaica major allergen. J Immunol 160 (1998) 2780-2785
14. Asturias J.A., Gómez-Bayón N., Eseverri J.L., and Martínez A. Par j 1 and Par j 2, the major allergens from Parietaria judaica pollen, have similar immunoglobulin E epitopes. Clin Exp Allergy 33 (2003) 518-524
15. Arilla M.C., González-Rioja R., Ibarrola I., Mir A., Monteseirín J., Conde J., et al. A sensitive monoclonal antibody-based enzyme-linked immunosorbent assay to quantify Parietaria judaica major allergens, Par j 1 and Par j 2. Clin Exp Allergy 36 (2006) 87-93
16. Bonura A., Amoroso S., Locorotondo G., Di Felice G., Tinghino R., Geraci D., et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 126 (2001) 32-40
17. Asturias J.A., Ibarrola I., Eraso E., Arilla M.C., and Martínez A. The major Platanus acerifolia pollen allergen Pla a 1 has sequence homology to invertase inhibitors. Clin Exp Allergy 33 (2003) 978-985
18. Ibarrola I., Sanz M.L., Gamboa P.M., Mir A., Benahmed D., Ferrer A., et al. Biological Characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 34 (2004) 303-309
19. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53 (1998) 1-42
20. van der Veen M.J., Mulder M., Witteman A.M., van Ree R., Aalberse R.C., Jansen H.M., et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 98 (1996) 1028-1034
21. Trivedi B., Valerio C., and Slater J.E. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 111 (2003) 777-783
22. Mothes N., Heinzkill M., and Drachenberg K.J. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvant vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by blocking antibodies. Clin Exp Allergy 33 (2003) 1198-1208
23. Moverate R., Elfman L., Vesterinen E., Metso T., and Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57 (2002) 423-430
24. Ball T., Sperr W.R., and Valent P. Introduction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 29 (1999) 2026-2036
25. Cortes L., Carvalho A.L., Todo-Bom A., Faro C., Pires E., and Veríssimo P. Purification of a novel aminopeptidase from the pollen of Parietaria judaica that alters epithelial integrity and degrades neuropeptides. J Allergy Clin Immunol 118 (2006) 878-884
26. Valenta R., and Kraft D. Recombinant allergens: from production and characterization to diagnosis, treatment, and prevention of allergy. Methods 32 (2004) 207-208
27. Linhart B., and Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 134 (2004) 324-331
28. Stumvoll S., Westritschnig K., Lidholm J., Spitzauer S., Colombo P., Duro G., et al. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 111 (2003) 974-979
29. González-Rioja R., Ferrer A., Arilla M.C., Ibarrola I., Viguera A.R., Andreu C., et al. Diagnosis of Parietaria judaica pollen allergy using natural and recombinant Par j 1 and Par j 2 allergens. Clin Exp Allergy 37 (2007) 243-250
30. Linhart B., Jahn-Schmid B., Verdino P., Keller W., Ebner C., Kraft D., et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 16 (2002) 1301-1303
31. Linhart B., Hartl A., Jahn-Schmid B., Verdino P., Keller W., and Valenta R. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115 (2005) 1010-1016
32. Aalberse R.C. Structural biology of allergens. J Allergy Clin Immunol 106 (2000) 228-238
33. Georgiou G., and Valax P. Expression of correctly folded proteins in Escherichia coli. Curr Opin Biotechnol 7 (1996) 190-197
34. Kussebi F., Karamloo F., Rhyner C., Schmid-Grendelmeier P., Salagianni M., Mannhart C., et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 115 (2005) 323-329
35. Vrtala S., Hirtenlehner K., Susani M., Akdis M., Kussebi F., Akdis C.A., et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J 15 (2001) 2045-2047
36. King T.P., Jim S.Y., Monsalve R.I., Kagey-Sobotka A., Lichtenstein L.M., and Spangfort M.D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 166 (2001) 6057-6065
37. Costa M.A., Duro G., Izzo V., Colombo P., Mirisola M.G., Locorotondo G., et al. The IgE-binding epitopes of rPar j 2, a major allergen of Parietaria judaica pollen, are heterogenously recognized among allergic subjects. Allergy 55 (2000) 246-250
38. Schramm G., Kahlert H., Suck R., Weber B., Stuwe H.T., Muller W.D., et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 162 (1999) 2406-2414
39. Bonura A., Corinti S., Artale A., Di Felice G., Amoroso S., Melis M., et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 142 (2007) 274-284
40. De Palma R., Wu S., Sallusto F., Di Felice G., Martucci P., Geraci D., et al. Use of antagonist peptides to inhibit in vitro T cell responses to Par j 1, the major allergen of Parietaria judaica pollen. J Immunol 162 (1999) 1982-1987
41. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
42. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 (2004) 14677-14682
43. Cromwell O., Fiebig H., Suck R., Kahlert H., Nandy A., Kettner J., et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin North Am 26 (2006) 261-281